Owen Hughes (L) and Patrick Baeuerle, Cullinan (Cullinan Oncology)
June 11, 2020 09:15 AM EDT
R&D

Fu­eled with a fresh cash in­jec­tion, Cul­li­nan ex­pands its pipeline with a bid to de­vel­op a new com­bi­na­tion drug for the check­point class

John Carroll

Editor & Founder

Fresh off of a $98.5 mil­lion raise, Patrick Baeuer­le’s team at Cul­li­nan On­col­o­gy has a new sub­sidiary they’re bring­ing in­to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Bay­er says elin­zane­tant quelled hot flash­es in women un­der­go­ing can­cer treat­ment

A service from the Financial Times